Azenta FY26 revenue $622M, up 5%; GAAP EPS -$3.50 on $149M impairment; FY27 revenue guided $648-660M

Azenta, Inc.

Q4 revenue $167M, +5% YoY (+2% organic); Sample Management Solutions $94M (+9%), Multiomics $73M flat; adjusted diluted EPS $0.28 vs $0.21 a year ago.
FY26 GAAP operating loss $174.7M and continuing-ops diluted EPS of -$3.50, including a $149M non-cash goodwill impairment; adjusted EPS $0.48 vs $0.51.
FY27 outlook: revenue $648-660M, organic growth 3-5%, adjusted EBITDA margin up 200-250 bps including 100 bps dilution from Elegen and SynPlexity; FCF up ~25%.
Acquired SynPlexity Oct 28 for $15M cash ($2.5M holdback) plus up to $10M contingent; Elegen license carries $23M fixed payments and a $25M perpetual conversion option.
B Medical Systems sold July 1, 2026, with the $35M vendor loan repaid Sept 3; FY26 repurchases totaled 4.4M shares for $118.2M, $131.8M left on the $250M program.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.